BioCentury | Dec 3, 2015
Distillery Therapeutics

Therapeutics: RAD23 homolog A (RAD23A; HR23A); RAD23 homolog B (RAD23B; HR23A)

...INDICATION: Amyotrophic lateral sclerosis (ALS) Studies in animals, patient samples and cell culture suggest inhibiting RAD23A...
...RAD23A and RAD23B expression. Next steps could include developing RAD23A and RAD23B inhibitors. TARGET/MARKER/PATHWAY: RAD23 homolog A (RAD23A...
...include developing RAD23A and RAD23B inhibitors. TARGET/MARKER/PATHWAY: RAD23 homolog A (RAD23A; HR23A ); RAD23 homolog B (RAD23B; HR23A...
BioCentury | Jul 15, 2013
Emerging Company Profile

Oxford Cancer: Functional silence is golden

Oxford Cancer Biomarkers Ltd. 's CancerNav cell-based screening platform may be able to more accurately identify genes that influence drug sensitivity than traditional in vitro methods that do not provide insight into a biomarker's functional...
BioCentury | Apr 1, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cutaneous T cell lymphoma (CTCL) RAD23 homolog B (RAD23B; HR23B); histone deacetylase (HDAC); proteasome In vitro and human studies suggest that HR23B could help predict...
Items per page:
1 - 3 of 3